Aurigene Highlights its PD-1 peptide, Bet Bromodomain and NAMPT Inhibitors Program at AACR 2013
BANGALORE, India and BRIDGEWATER, New Jersey, April 2, 2013 /PRNewswire/ --
Aurigene will be presenting poster sessions for three of its programs at the American Associate of Cancer Research (April 6-10 in Washington, DC).
PD-1 is a 29-amino acid novel peptide (NP-12) that displays sub-nM potency in disruption of PD1-PDL1/L2 interactions. NP-12 is highly effective in antagonizing PD1 signalling, with desirable in vivo exposure upon s.c. dosing. NP-12 inhibits tumor growth and metastasis in preclinical models of cancer and is well tolerated with no overt toxicity at any of the tested doses; currently in IND studies.
Session Title: Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway
ID: Cytokines, Modification of the Tumor Microenvironment, and Intervention - 1231/11 PO.IM02.02.
Date and Time: Mon, Apr 8, 1:00 - 5:00 PM
Bet Bromodomain: Aurigene has identified novel chemical series of lead compounds that show excellent cell based activity. Demonstration of efficacy is on-going.
Session Title: Identification of potent BET bromodomain inhibitors for treatment of cancer
ID: Epigenetic Therapy and Risk Biomarkers 671/1 - PO.MCB06.05.
Date and Time: Sun, Apr 7, 1:00 - 5:00 PM
NAMPT: Aurigene has identified novel chemical series of compounds - lead compounds show excellent cell based activity correlating with biochemical potency, favorable ADME profile, excellent pharmacokinetic profile in mice with good oral bioavailability. The lead compound shows excellent efficacy with tumor regression in pancreatic cancer xenograft mice models. Preclinical studies on-going.
Session Title: Novel inhibitors of nicotinamide phosphoribosyl transferase (NAMPT)
ID: Molecular and Cellular Biology 72
Date and Time: Wednesday Apr 10, 2013 8:00 AM - 12:00 PM
Location: Hall A-C, Poster Section 33
Revised Permanent Abstract Number: 5389
Aurigene is an India based biotech focussed on small molecule and peptide therapeutics for oncology, inflammation and anti-infectives. Our current pipeline includes several best-in-class and first-in-class assets for oncology and inflammation in preclinical/ IND stage. The most advanced programs include (a) PD-1 peptide therapy for oncology and antibacterial infections; (b) Matriptase - a novel protease for OA currently in preclinical studies; (c) FabI inhibitor in IND studies for MRSA. In addition, Aurigene is building a robust pipeline of early stage assets in emerging areas of cancer metabolism, epigenetics and the TH17 pathway. For more information, please visit the company's website at http://www.aurigene.com.
Head Strategic Alliances